Physician profile
Charles D Ericsson
NPI 1477571941
$5,690.29
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,743 · 2020: $3,826 · 2021: $121.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Redhill Biopharma INC. | $3,500.00 | 2020 | |
| Melinta Therapeutics, LLC | $567.57 | 2019 | |
| Merck Sharp & Dohme LLC | $424.10 | 2019-2020 | |
| Insmed, INC. | $289.98 | 2019-2021 | |
| Tetraphase Pharmaceuticals, INC. | $275.85 | 2019 | |
| Paratek Pharmaceuticals, INC. | $199.08 | 2019-2020 | |
| Astellas Pharma US INC | $185.28 | 2019-2020 | |
| Allergan, INC. | $124.81 | 2019 | |
| Stryker Corporation | $44.81 | 2021 | |
| Pfizer INC. | $28.49 | 2019 | |
| Abbvie INC. | $21.46 | 2021 | |
| Nabriva Therapeutics, Plc | $16.59 | 2020 | |
| Shionogi INC | $12.27 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Ericsson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.